Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
Introduction Chimeric antigen receptor (CAR) T cells spark hope for patients with CD19+ B cell neoplasia, including relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) or r/r non-Hodgkin’s lymphoma (NHL). Published studies have mostly used second-generation CARs with 4-1BB or CD28 as co...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
May 19 2019
|
| In: |
BMJ open
Year: 2019, Jahrgang: 9, Heft: 5, Pages: 1-15 |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2018-026644 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1136/bmjopen-2018-026644 Verlag, kostenfrei, Volltext: https://bmjopen.bmj.com/content/9/5/e026644 
|
| Verfasserangaben: | Maria-Luisa Schubert, Anita Schmitt, Leopold Sellner, Brigitte Neuber, Joachim Kunz, Patrick Wuchter, Alexander Kunz, Ulrike Gern, Birgit Michels, Susanne Hofmann, Angela Hückelhoven-Krauss, Andreas Kulozik, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1691172243 | ||
| 003 | DE-627 | ||
| 005 | 20241126131235.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200227s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2018-026644 |2 doi | |
| 035 | |a (DE-627)1691172243 | ||
| 035 | |a (DE-599)KXP1691172243 | ||
| 035 | |a (OCoLC)1341308424 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schubert, Maria-Luisa |d 1982- |e VerfasserIn |0 (DE-588)1147867631 |0 (DE-627)1007273801 |0 (DE-576)49608089X |4 aut | |
| 245 | 1 | 0 | |a Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector |b a unicentre phase I/II clinical trial protocol |c Maria-Luisa Schubert, Anita Schmitt, Leopold Sellner, Brigitte Neuber, Joachim Kunz, Patrick Wuchter, Alexander Kunz, Ulrike Gern, Birgit Michels, Susanne Hofmann, Angela Hückelhoven-Krauss, Andreas Kulozik, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt |
| 264 | 1 | |c May 19 2019 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First published on May 19, 2019 | ||
| 500 | |a Gesehen am 27.02.2020 | ||
| 520 | |a Introduction Chimeric antigen receptor (CAR) T cells spark hope for patients with CD19+ B cell neoplasia, including relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) or r/r non-Hodgkin’s lymphoma (NHL). Published studies have mostly used second-generation CARs with 4-1BB or CD28 as costimulatory domains. Preclinical results of third-generation CARs incorporating both elements have shown superiority concerning longevity and proliferation. The University Hospital of Heidelberg is the first institution to run an investigator-initiated trial (IIT) CAR T cell trial (Heidelberg Chimeric Antigen Receptor T cell Trial number 1 [HD-CAR-1]) in Germany with third-generation CD19-directed CAR T cells. - Methods and analysis Adult patients with r/r ALL (stratum I), r/r NHL including chronic lymphocytic leukaemia, diffuse large B-cell lymphoma, follicular lymphoma or mantle cell lymphoma (stratum II) as well as paediatric patients with r/r ALL (stratum III) will be treated with autologous T-lymphocytes transduced by third-generation RV-SFG.CD19.CD28.4-1BB zeta retroviral vector (CD19.CAR T cells). The main purpose of this study is to evaluate safety and feasibility of escalating CD19.CAR T cell doses (1-20×106 transduced cells/m2) after lymphodepletion with fludarabine (flu) and cyclophosphamide (cyc). Patients will be monitored for cytokine release syndrome (CRS), neurotoxicity, i.e. CAR-T-cell-related encephalopathy syndrome (CRES) and/or other toxicities (primary objectives). Secondary objectives include evaluation of in vivo function and survival of CD19.CAR T cells and assessment of CD19.CAR T cell antitumour efficacy.HD-CAR-1 as a prospective, monocentric trial aims to make CAR T cell therapy accessible to patients in Europe. Currently, HD-CAR-1 is the first and only CAR T cell IIT in Germany. A third-generation Good Manufacturing Practice (GMP) grade retroviral vector, a broad spectrum of NHL, treatment of paediatric and adult ALL patients and inclusion of patients even after allogeneic stem cell transplantation (alloSCT) make this trial unique. - Ethics and dissemination Ethical approval and approvals from the local and federal competent authorities were granted. Trial results will be reported via peer-reviewed journals and presented at conferences and scientific meetings. - Trial registration number Eudra CT 2016-004808-60; NCT03676504; Pre-results. | ||
| 650 | 4 | |a 4-1bb (cd137), Cd28 Costimulatory Domains | |
| 650 | 4 | |a CD19 CAR T cells | |
| 650 | 4 | |a refractory Or relapsed leukaemia and lymphoma | |
| 650 | 4 | |a third-generation car T cells | |
| 700 | 1 | |a Schmitt, Anita |d 1969- |e VerfasserIn |0 (DE-588)141722495 |0 (DE-627)630587752 |0 (DE-576)325593892 |4 aut | |
| 700 | 1 | |a Sellner, Leopold |d 1984- |e VerfasserIn |0 (DE-588)143493825 |0 (DE-627)646576704 |0 (DE-576)337362963 |4 aut | |
| 700 | 1 | |a Neuber, Brigitte |d 1974- |e VerfasserIn |0 (DE-588)1052913563 |0 (DE-627)789293188 |0 (DE-576)408653884 |4 aut | |
| 700 | 1 | |a Kunz, Joachim |d 1974- |e VerfasserIn |0 (DE-588)124297730 |0 (DE-627)085769029 |0 (DE-576)294107703 |4 aut | |
| 700 | 1 | |a Wuchter, Patrick |d 1975- |e VerfasserIn |0 (DE-588)123450284 |0 (DE-627)082563624 |0 (DE-576)184642574 |4 aut | |
| 700 | 1 | |a Kunz, Alexander |e VerfasserIn |0 (DE-588)1195494173 |0 (DE-627)1677545046 |4 aut | |
| 700 | 1 | |a Gern, Ulrike |e VerfasserIn |0 (DE-588)1076031390 |0 (DE-627)834091364 |0 (DE-576)444801170 |4 aut | |
| 700 | 1 | |a Michels, Birgit |e VerfasserIn |0 (DE-588)1160962138 |0 (DE-627)1024351122 |0 (DE-576)50629031X |4 aut | |
| 700 | 1 | |a Hofmann, Susanne |e VerfasserIn |0 (DE-588)1147869723 |0 (DE-627)1007274824 |0 (DE-576)496081845 |4 aut | |
| 700 | 1 | |a Hückelhoven-Krauss, Angela |d 1983- |e VerfasserIn |0 (DE-588)1034095889 |0 (DE-627)744057280 |0 (DE-576)381742822 |4 aut | |
| 700 | 1 | |a Kulozik, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1025736567 |0 (DE-627)723892032 |0 (DE-576)167091638 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Dreger, Peter |e VerfasserIn |0 (DE-588)1028891881 |0 (DE-627)732699894 |0 (DE-576)376320966 |4 aut | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d London : BMJ Publishing Group, 2011 |g 9(2019), 5, Artikel-ID e026644, Seite 1-15 |h Online-Ressource |w (DE-627)654747075 |w (DE-600)2599832-8 |w (DE-576)339269340 |x 2044-6055 |7 nnas |a Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector a unicentre phase I/II clinical trial protocol |
| 773 | 1 | 8 | |g volume:9 |g year:2019 |g number:5 |g elocationid:e026644 |g pages:1-15 |g extent:15 |a Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector a unicentre phase I/II clinical trial protocol |
| 856 | 4 | 0 | |u https://doi.org/10.1136/bmjopen-2018-026644 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://bmjopen.bmj.com/content/9/5/e026644 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200227 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |e 910000PS133177173 |e 910100PS133177173 |k 0/910000/ |k 1/910000/910100/ |p 16 |y j | ||
| 998 | |g 1028891881 |a Dreger, Peter |m 1028891881:Dreger, Peter |d 910000 |d 910100 |e 910000PD1028891881 |e 910100PD1028891881 |k 0/910000/ |k 1/910000/910100/ |p 15 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 14 | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 13 | ||
| 998 | |g 1025736567 |a Kulozik, Andreas |m 1025736567:Kulozik, Andreas |d 910000 |d 910100 |e 910000PK1025736567 |e 910100PK1025736567 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 1034095889 |a Hückelhoven-Krauss, Angela |m 1034095889:Hückelhoven-Krauss, Angela |d 910000 |d 910100 |e 910000PH1034095889 |e 910100PH1034095889 |k 0/910000/ |k 1/910000/910100/ |p 11 | ||
| 998 | |g 1147869723 |a Hofmann, Susanne |m 1147869723:Hofmann, Susanne |d 910000 |d 910100 |e 910000PH1147869723 |e 910100PH1147869723 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 998 | |g 1160962138 |a Michels, Birgit |m 1160962138:Michels, Birgit |d 910000 |d 910100 |e 910000PM1160962138 |e 910100PM1160962138 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 998 | |g 1076031390 |a Gern, Ulrike |m 1076031390:Gern, Ulrike |d 910000 |d 910100 |e 910000PG1076031390 |e 910100PG1076031390 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1195494173 |a Kunz, Alexander |m 1195494173:Kunz, Alexander |d 910000 |d 910100 |e 910000PK1195494173 |e 910100PK1195494173 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 123450284 |a Wuchter, Patrick |m 123450284:Wuchter, Patrick |d 60000 |d 63500 |e 60000PW123450284 |e 63500PW123450284 |k 0/60000/ |k 1/60000/63500/ |p 6 | ||
| 998 | |g 124297730 |a Kunz, Joachim |m 124297730:Kunz, Joachim |d 910000 |d 910100 |e 910000PK124297730 |e 910100PK124297730 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1052913563 |a Neuber, Brigitte |m 1052913563:Neuber, Brigitte |d 910000 |d 910100 |e 910000PN1052913563 |e 910100PN1052913563 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 143493825 |a Sellner, Leopold |m 143493825:Sellner, Leopold |d 910000 |d 910100 |e 910000PS143493825 |e 910100PS143493825 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 141722495 |a Schmitt, Anita |m 141722495:Schmitt, Anita |d 910000 |d 910100 |e 910000PS141722495 |e 910100PS141722495 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1147867631 |a Schubert, Maria-Luisa |m 1147867631:Schubert, Maria-Luisa |d 910000 |d 910100 |e 910000PS1147867631 |e 910100PS1147867631 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1691172243 |e 3598968108 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"15 S."}],"language":["eng"],"recId":"1691172243","id":{"doi":["10.1136/bmjopen-2018-026644"],"eki":["1691172243"]},"name":{"displayForm":["Maria-Luisa Schubert, Anita Schmitt, Leopold Sellner, Brigitte Neuber, Joachim Kunz, Patrick Wuchter, Alexander Kunz, Ulrike Gern, Birgit Michels, Susanne Hofmann, Angela Hückelhoven-Krauss, Andreas Kulozik, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt"]},"relHost":[{"note":["Gesehen am 02.10.20"],"title":[{"title_sort":"BMJ open","title":"BMJ open"}],"pubHistory":["2011 -"],"origin":[{"dateIssuedKey":"2011","publisher":"BMJ Publishing Group","dateIssuedDisp":"2011-","publisherPlace":"London"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector a unicentre phase I/II clinical trial protocolBMJ open","physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"9","pages":"1-15","extent":"15","year":"2019","issue":"5","text":"9(2019), 5, Artikel-ID e026644, Seite 1-15"},"language":["eng"],"recId":"654747075","id":{"eki":["654747075"],"zdb":["2599832-8"],"issn":["2044-6055"]}}],"note":["First published on May 19, 2019","Gesehen am 27.02.2020"],"person":[{"display":"Schubert, Maria-Luisa","given":"Maria-Luisa","family":"Schubert","role":"aut"},{"given":"Anita","family":"Schmitt","display":"Schmitt, Anita","role":"aut"},{"given":"Leopold","family":"Sellner","display":"Sellner, Leopold","role":"aut"},{"family":"Neuber","given":"Brigitte","display":"Neuber, Brigitte","role":"aut"},{"role":"aut","given":"Joachim","family":"Kunz","display":"Kunz, Joachim"},{"display":"Wuchter, Patrick","family":"Wuchter","given":"Patrick","role":"aut"},{"role":"aut","family":"Kunz","given":"Alexander","display":"Kunz, Alexander"},{"role":"aut","display":"Gern, Ulrike","family":"Gern","given":"Ulrike"},{"display":"Michels, Birgit","given":"Birgit","family":"Michels","role":"aut"},{"display":"Hofmann, Susanne","given":"Susanne","family":"Hofmann","role":"aut"},{"display":"Hückelhoven-Krauss, Angela","given":"Angela","family":"Hückelhoven-Krauss","role":"aut"},{"role":"aut","display":"Kulozik, Andreas","family":"Kulozik","given":"Andreas"},{"role":"aut","display":"Ho, Anthony Dick","given":"Anthony Dick","family":"Ho"},{"role":"aut","display":"Müller-Tidow, Carsten","family":"Müller-Tidow","given":"Carsten"},{"role":"aut","family":"Dreger","given":"Peter","display":"Dreger, Peter"},{"role":"aut","display":"Schmitt, Michael","given":"Michael","family":"Schmitt"}],"title":[{"title":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector","title_sort":"Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector","subtitle":"a unicentre phase I/II clinical trial protocol"}],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"May 19 2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a SCHUBERTMATREATMENTO1920 | ||